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IL-10 is a prototypical anti-inflammatory cytokine, which is fundamental to the maintenance of
immune homeostasis, especially in the intestine. There is an assumption that cells producing IL-
10 have an immunoregulatory function. However, here we report that IL-10-producing CD4+
T cells are phenotypically and functionally heterogeneous. By combining single cell tran-
scriptome and functional analyses, we identified a subpopulation of IL-10-producing Foxp3neg
CD4+ T cells that displays regulatory activity unlike other IL-10-producing CD4+ T cells, which
are unexpectedly pro-inflammatory. The combinatorial expression of co-inhibitory receptors is
sufficient to discriminate IL-10-producing CD4+ T cells with regulatory function from others
and to identify them across different tissues and disease models in mice and humans. These
regulatory IL-10-producing Foxp3neg CD4+ T cells have a unique transcriptional program,
which goes beyond the regulation of IL-10 expression. Finally, we found that patients with
Inflammatory Bowel Disease demonstrate a deficiency in this specific regulatory T-cell
subpopulation.
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Immune mediated inflammatory diseases (IMIDs) are char-acterized by a dysregulated immune response and non-healingtissue damage, which promotes a vicious cycle leading to
chronic disease. What breaks immunological tolerance in these
diseases is unknown and therefore medical therapies currently
used to treat IMIDs are as of yet, not curative. Mouse studies have
shown that regulatory CD4+ T cells and the production of the
anti-inflammatory cytokine interleukin-10 (IL-10) represent
fundamental mechanisms to maintain the immunological toler-
ance especially in the intestine. Moreover, human genetics studies
have shown that polymorphisms in genes associated with the
regulatory mechanisms of CD4+ T cells, such as interleukin-10
(IL10) and IL10RA are associated with early onset intestinal
inflammation1,2. Thus, a defect in these mechanisms could be
involved in the pathogenesis of IMIDs, especially in inflammatory
bowel disease (IBD). Nevertheless, in contrast to what would be
expected on the basis of these data, IBD patients do not show an
obvious defect in IL-10 production3–5. One hypothesis to explain
this discrepancy, would be that only a subpopulation of IL-10-
producing CD4+ T cells has regulatory activity. Therefore, the
quantification of all IL-10-producing CD4+ T cells could have
been misleading, since it does not allow the quantification of this
potentially hidden subpopulation. An example supporting this
hypothesis is represented by one type of regulatory T cells, namely
Foxp3+ CD4+ T cells. These cells have been subdivided into
subpopulations based on their heterogeneous regulatory activity.
This stratification was essential to understand their contribution to
the prognosis of patients with colorectal cancer6. Despite this, no
reproducible defect in number or function of Foxp3+ regulatory
T cells could be observed in patients suffering from IBD7–9.
Also, IL-10-producing Foxp3negative (neg) CD4+ T cells, usually
referred to as T regulatory type 1 cells (TR1), have a powerful
regulatory activity. However, whether this population of cells is a
functional homogenous population across different tissues and
species remains unknown. Different groups have described that
several surface molecules, including co-inhibitory receptors such
as LAG-3, PD1, and TIM-3 and also other integrins and che-
mokines such as CD49b and CCR5, can be expressed by IL-10-
producing Foxp3neg CD4+ T cells10–19. Notably, we and others
already observed in distinct studies that not all IL-10-producing
CD4+ T cells co-express LAG-3 and CD49b11 or TIM-3, TIGIT,
PD1, and CCR512,20. These data already suggested a potential
functional heterogeneity, especially considering that co-inhibitory
receptors are not just surface markers, but they also fulfill a
regulatory function. However, it remains to be addressed whether
there is a significant difference between those IL-10-producing
Foxp3neg CD4+ T cells, which express the surface markers and
those which, despite IL-10 expression, do not express them.
By studying IL-10-producing Foxp3neg CD4+ T cells, several
transcriptional factors that regulate Il10 expression have been
identified. Blimp1 and C-maf21, through EGR-222,23, promote the
transactivation of the Il10 gene. More recently, IRF1, BATF,
Eomes, and T-cell receptor induced ITK were shown to be key
factors in the development of these cells24–26. However, the
transcriptional program that goes beyond the regulation of IL-10
and defines the identity of IL-10-producing Foxp3neg regulatory
CD4+ T cells has not been yet identified.
Here, by combining transcriptomic analysis at the resolution of
single cells and functional experiments in mouse and humans we
have shown that IL-10-producing Foxp3neg CD4+ T cells are a
functionally heterogeneous population of cells. The combinatorial
expression of co-inhibitory receptors allowed the identification of
a subpopulation with a regulatory function. This subpopulation
displayed a unique molecular program. Finally IBD patients
showed a selective paucity of these regulatory cells.
Results
IL-10-producing CD4+ T cells are heterogeneous. It has been
assumed that all IL-10-producing T cells are a functionally
homogenous population of anti-inflammatory cells. To challenge
this assumption, we isolated IL-10-producing (IL-10positive (pos))
Foxp3neg CD4+ T cells - we excluded Foxp3 expressing cells, as
their functional heterogeneity has been already described - from
small intestine and spleen using IL-10eGFP, Foxp3mRFP double
reporter mice upon in vivo expansion of this cell population via
anti-CD3 antibody (mAb) treatment11,27–29. The function of
these cells was then assessed in a T-cell mediated transfer colitis
mouse model27,28,30. Unexpectedly, transfer of splenic IL-10-
producing Foxp3neg CD4+ T cells caused colitis upon transfer,
while small intestinal IL-10-producing Foxp3neg CD4+ T cells did
not cause colitis as expected (Fig. 1a–c).
These data could be explained at least by two not mutually
exclusive hypotheses: (i) only intestinal IL-10-producing Foxp3neg
CD4+ T cells have a regulatory activity or (ii) splenic IL-10-
producing Foxp3neg CD4+ T cells are a functionally hetero-
geneous population of cells consisting of a minority of
suppressive cells that are outnumbered by a majority of
inflammatory cells. To test the potential heterogeneity of IL-10-
producing Foxp3neg CD4+ T cells, we performed single cell RNA
sequencing (scRNA-seq), using two complementary methods. As
a control, we included IL-10-producing Foxp3+ CD4+ T cells
(Supplementary Figure 1A). First, we used SMART-seq2 scRNA-
seq protocol, which provides good sequencing depth, but few cells
to analyze (Supplementary Figure 1). After quality control and
excluding cells in G2 cell cycle or S-phase, we analyzed 138 small
intestinal and 388 splenic IL-10eGFP+ CD4+ T cells. We validated
that 92% of eGFP+ sorted cells indeed expressed Il10.
Furthermore, there was a robust correlation between Il10 and
eGfp (Supplementary Figure 1B). We then performed a t-
distributed stochastic neighbor embedding (t-SNE) analysis and
found that the cells isolated from the spleen form more distinct
clusters than those isolated from the intestine (4 clusters in spleen
vs. 2 clusters in small intestine, Supplementary Figure 1C). To
further strengthen this observation, we performed a bootstrap
analysis by selecting 100 random cells and computing the number
of highly variable genes (HVGs) in each organ. We observed that
IL-10-producing cells in the spleen have more variable genes than
those in the intestine (Supplementary Figure 1D). Taken together,
these analyses suggest a higher heterogeneity of IL-10-producing
T cells isolated from the spleen compared to the small intestine
(Supplementary Figure 1).
We next used the Drop-seq based 10X technology to validate
these data. We analyzed 1379 small intestinal and 1665 splenic
IL-10eGFP+ CD4+ T cells after quality filtering and normal-
ization. As observed before, the t-SNE analysis revealed more
distinct clusters amongst IL-10eGFP+ CD4+ T cells derived from
the spleen than from the small intestine (Fig. 1d). In particular,
cells from the small intestine separated into 4 different clusters (SI
C1-C4), among which the two largest clusters (SI C1 and C2)
were relatively similar based on genes that were expressed. In the
spleen, however, cells segregated into 7 clusters (Sp C1-C7).
Furthermore, the number of HVGs was higher in IL-10-
producing cells from the spleen compared to the small intestine
(Fig. 1e). A further analysis revealed that both Sp C5 and Sp C4
contained Foxp3 expressing cells, confirming the transcriptional
heterogeneity of Foxp3+ T cells (Fig. 1f). Interestingly, Sp C5 was
defined by high expression of Ikzf2 (encoding HELIOS) as well as
Il2ra, Ctla4, and Icos, which are central hallmarks of Foxp3+ Treg
cells31–35, while these genes were lower in Sp C4 (Supplementary
Figure 2). Finally, we observed that the expression of co-
inhibitory receptors, which have been shown to be expressed on
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TR1 cells, such as Lag3, Ctla4, and Havcr2 (encoding TIM-3) was
different across distinct clusters (Fig. 1f).
Collectively, these data revealed a remarkable degree of
heterogeneity amongst splenic IL-10-producing Foxp3neg CD4+
T cells. Thus, it could also be possible that these subpopulations
might have different functions: pro- or anti-inflammatory. From
here on we focused on the identification of cell clusters with an
anti-inflammatory phenotype amongst splenic IL-10-producing
Foxp3neg CD4+ T cells. To identify this cluster, we analyzed the
similarity between splenic and small intestinal cell clusters: the
potentially hidden regulatory cluster in the spleen might resemble
the anti-inflammatory clusters present in the intestine. To this
end, we calculated the Spearman correlation coefficient between
each cluster from small intestine and spleen (Fig. 2a). SI C1 and
Sp C1 had the highest similarity (0.912). Fold change analysis of
genes highly enriched in those clusters, revealed that 35 out of 100
top enriched genes were shared by both clusters (Fig. 2b).
Amongst these, we found cytokine-encoding genes, such as Ifng
and Il10 (Figs. 1f and 2b, c). High Il10 expression was
accompanied by high expression of Maf, which is a crucial
transcription factor for Il10 expression36. Id2 was also very highly
expressed by both clusters and has already been linked to the
maintenance of regulatory T cells37,38 (Fig. 2b, d). Besides
secretion of IL-10, granzyme secretion is another important
suppressive mechanism of human and mouse TR1 cells39,40.
Interestingly, Gzmb was indeed one gene defining both clusters
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Fig. 1 Mouse IL-10-producing CD4+ T cells are heterogeneous. a–c IL-10-producing Foxp3neg CD4+ T cells (IL-10pos) were isolated from small intestine or
spleen of aCD3-treated IL-10eGFP Foxp3mRFP double reporter mice. Cells were transferred into lymphopenic hosts and colitis development was assessed by
weight loss (c) and endoscopic colitis score (b) 5 weeks upon transfer (IL-10pos cells small intestine n= 12; IL-10pos cells Spleen n= 11; lines indicate mean
±SEM). Results are cumulative of three independent experiments. A Mann–Whitney U test was used to calculate significance. d t-SNE analysis of single cell
RNA sequencing of IL-10pos cells (including Foxp3+ cells) isolated from small intestine or spleen of aCD3-treated IL-10eGFP Foxp3mRFP double reporter
mice. e Bootstrap analysis of HVGs in single cell RNA sequencing data of IL-10pos cells from small intestine and spleen. f Expression of indicated genes in t-
SNE analysis
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(Fig. 2b, e). Concurrent with the high expression of Gzmb, both SI
C1 and Sp C1 were defined by high expression of Serpinb6b and
Serpinb9 (Fig. 2b, e). Serpinb proteins have been demonstrated to
be essential to protect granzyme B-secreting regulatory T cells
from self-inflicted damage41,42. Also, Lilrb4 has been linked with
regulatory functions in T cells and other immune cell subsets,
even though much less understood43–45, and was more highly
expressed in Sp C1 and SI C1 compared to other clusters (Fig. 2b,
e). Finally, we found that both Sp C1 and SI C1 were
characterized by high expression of Lag3, Ccr5, Ctla4, Il12rb2,
and Tnfrsf18 (Fig. 1f, Fig. 2b, f). LAG-3, CTLA4, and CCR5 are
known surface markers of TR1 cells11,12 and IL12Rβ246,47 and
GITR (encoded by Tnfrsf18) play a key role in inducing
regulatory cells and their function48–50.
Taken together, IL-10-producing Foxp3neg CD4+ T cells are a
transcriptionally heterogeneous cell population. Furthermore, one
cluster of splenic IL-10-producing Foxp3neg CD4+ T cells
resembled the main cluster seen in the small intestine, and it is
characterized by expression of genes associated with TR1 cell
biology.
Co-inhibitory receptors identify a regulatory subpopulation.
We aimed to further test, if splenic IL-10-producing Foxp3neg
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Fig. 2 Splenic IL-10-producing CD4+ T cells contain a regulatory cluster. a Spearman correlation coefficient between each cluster from small intestine and
spleen. b Fold change analysis of genes enriched in indicated clusters compared to other clusters that were amongst the 100 most enriched genes.
c Expression of indicated genes encoding cytokines and chemokines. d Expression of indicated genes encoding transcription factors. e Expression of
indicated genes encoding other factors. f Expression of indicated genes encoding surface receptors
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CD4+ T cells are a functionally heterogeneous population of cells.
To this end, we had to be able to isolate the candidate suppressive
population/s of cells. Notably, among the HVGs previously
described, we found genes encoding for co-inhibitory receptors
and other TR1 cell associated surface markers. For instance, Lag3
and Ccr5 were highly expressed in both Sp C1 and SI C1 (Fig. 2b,
f). Additionally, Havcr2 (encoding TIM-3) was highly expressed
by cells in Sp C1 (Fig. 1f; Supplementary Figure 2). Thus, we
analyzed whether the simultaneous expression of several surface
molecules allows the isolation of cells enriched in the Sp C1
population. First we confirmed that co-inhibitory receptors (i.e.
LAG-3, TIGIT, TIM-3, and PD-1) and TR1 associated surface
markers (i.e. CD49b and CCR5) were most abundantly expressed
by IL-10-producing Foxp3neg CD4+ T cells compared to IL-10
negative T cells. Second, we found in all analyzed organs and
models that some of the IL-10-producing Foxp3neg CD4+ T cells
were negative for co-inhibitory markers (Supplementary Fig-
ure 3). Then, in order to visualize the complexity of this multi-
parameter analysis we used viSNE analysis51. We found that the
expression of the analyzed markers varied drastically across IL-
10-producing Foxp3neg CD4+ T cells within one and different
tissues (Fig. 3a, blue circle). However, we consistently identified a
subpopulation that contained cells enriched for all co-inhibitory
receptors and the other surface molecules tested. From here on
we refer to this IL-10-producing Foxp3neg CD4+ T cells as co-
inhibitory receptor (CIR) rich population. Interestingly, one
major difference between the analyzed tissues was the frequency
of CIR rich CD4+ T cells. While in the small intestine of anti-
CD3 treated animals more than half of the analyzed cells were
CIR rich, these cells represented a minority in the spleen, where
only 10% of them were found (Fig. 3a, right panel). Furthermore,
we confirmed our findings under steady state conditions in small
intestine and during P. berghei infection, a model of Malaria52, in
spleen and liver (Fig. 3b, c).
Thus, using a multi-parameter analysis we identified a
subpopulation of IL-10-producing Foxp3neg CD4+ T cells, which
express simultaneously several IL-10 associated markers across
different tissues and mouse models.
CIR rich cells are suppressive. Next, we tested whether IL-10-
producing Foxp3neg CIR rich CD4+ T cells have a distinct
function from IL-10-producing Foxp3neg CIR poor cells. To this
end, we had to be able to isolate these CIR rich and CIR poor cells
from spleens of anti-CD3 treated or P. berghei infected IL-10eGFP
Foxp3mRFP double reporter mice and then tested their suppres-
sive capacity. Since viSNE cannot be used for FACS sorting, we
assessed the specificity and sensitivity of different sets of markers
to isolate CIR rich cells. The result of this analysis showed that
among several combinations of markers, the co-expression of IL-
10eGFP, CD49b, and LAG-3 had the highest sensitivity and still a
specificity of over 90% for detecting CIR rich cells. We also tested
whether high IL-10 expression is sufficient to identify IL-10-
producing Foxp3neg CIR rich CD4+ T cells. However, this had
the lowest sensitivity and specificity among all the combinations
of markers tested (Supplementary Figure 4A and B).
After having established the use of CD49b/LAG-3/IL-10 as the
most efficient gating strategy, we then FACS-sorted splenic CIR
rich and CIR poor cells (Supplementary Figure 5) from both anti-
CD3 treated and P. berghei infected mice and tested their
suppressive capacity in vitro. We found that CIR rich cells had a
high in vitro suppressive capacity in contrast to CIR poor cells
(Fig. 4a, b). There was a correlation, by trend and in some organs,
between IL-10 expression and CIR rich cells (Supplementary
Figure 4C). Therefore, in order to assess whether differences in
IL-10 production might account for the different suppressive
activity we did two additional experiments. We performed an
in vitro suppressive experiment using CIR rich and CIR poor cells
isolated from liver of P. berghei infected mice: In this organ the
IL-10eGFP MFI among CIR rich and CIR poor is equal
(Supplementary Figure 4C). Also in this case, CIR rich cells
had a superior in vitro suppressive capacity compared to IL-10-
producing Foxp3neg CIR poor cells (Supplementary Figure 4D).
Furthermore, we performed in vitro suppressive assays compar-
ing IL-10intermediate CIR rich with IL-10intermediate CIR poor cells
isolated form the spleen of the anti-CD3 treated mice in order to
assure that we analyze populations with equal IL-10 production.
We found that also the IL-10intermediate CIR rich had a higher
suppressive capacity compared to CIR-poor cells (Supplementary
Figure 4E).
We next wondered whether CIR rich and CIR poor cells
differed only in their suppressive activity or also in the
mechanisms of function. Due to the co-expression of several
co-inhibitory receptors, we hypothesized that CIR rich cells have
a large portfolio of regulatory mechanisms (e.g. co-inhibitors
receptor). Indeed, we found that blockage of either LAG-3, or
TIM-3 or IL-10 receptor signaling alone only slightly affected the
suppressive capacity of CIR rich cells. However, blocking all
three, LAG-3, TIM-3, and IL-10 receptor signaling, reduced the
suppressive capacity of CIR rich cells to the level of CIR-poor
cells (Fig. 4c).
We then divided the splenic IL-10-producing Foxp3neg CD4+
T cells, which promoted colitis when transferred as one
population in Rag1 deficient mice (Fig. 1a–c), into CIR rich
and CIR poor cells and tested their pathogenicity in vivo. CIR
rich cells were indeed non-pathogenic, while CIR poor cells
induced moderate to severe colitis (Fig. 4d). As control, we used
IL-10neg CD4+ T cells, which induced severe colitis as expected.
To finally test the suppressive capacity of CIR rich cells, we co-
transferred these cells together with IL-10neg CD4+ T cells into
lymphopenic hosts (Fig. 4e). CIR rich cells were able to prevent
intestinal disease to a similar extent as Foxp3+ Treg cells (Fig. 4e).
Additionally, we tested if the anti-colitogenic effect of CIR cells
was dependent on IL-10. To this end, we co-transferred CIR cells
with IL-10neg CD4+ T cells isolated from either wild type or
transgenic mice with T-cell specific over expression of a dominant
negative IL-10Rα (IL-10Rimpaired), in which IL-10 signaling is
largely impaired29. In this case, CIR rich failed to supress disease
mediated by effector T cells with impaired IL-10 signaling
(Supplementary Figure 6A). These data indicate that the
suppressive capacity of CIR cells during colitis depends on IL-10.
Finally, to investigate why CIR poor cells were pathogenic
(Fig. 4d), we tested their stability. We found that CIR poor cells
lose the expression of IL-10 upon in vitro re-stimulation, while
CIR rich cells retained the expression of IL-10 (Supplementary
Figure 6B). Thus CIR poor cells have a less stable phenotype
compared to CIR rich cells.
In summary, we demonstrated that only a subpopulation of
splenic IL-10-producing Foxp3neg CD4+ T cells has anti-
inflammatory function. This subpopulation is characterized by
the co-expression of co-inhibitory receptors and is present across
different organs and disease models. It relies on several
mechanisms of suppression, but IL-10 is fundamental during
colitis. Thus, these data support the hypothesis that IL-10-
producing Foxp3neg CD4+ T cells are a functionally hetero-
geneous population of cells.
Transcriptional program of CIR rich CD4+ T cells. Our data
suggest that non-regulatory CD4+ T cells also express IL-10.
Thus, the transcription factors regulating Il10 expression
might be necessary but not sufficient to define regulatory
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Fig. 4 CIR rich CD4+ T cells have a high suppressive capacity. a In vitro suppression of co-inhibitory receptor rich (CIR rich) and co-inhibitory receptor poor
(CIR poor) IL-10pos Foxp3neg CD4+ T cells isolated from spleen of aCD3-treated IL-10eGFP Foxp3mRFP double reporter mice. Representative histograms of
five independent experiments, a paired T-test was used to calculate significance. b In vitro suppression of CIR rich and CIR poor IL-10pos Foxp3neg CD4+
T cells isolated from spleen of P. berghei infected IL-10eGFP Foxp3mRFP double reporter mice. Representative histograms of four independent experiments. c In
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IL-10-producing Foxp3neg CD4+ T cells. Therefore, to go beyond
the transcriptional factors regulating the expression of Il10, we
profiled the transcriptome of regulatory CIR rich cells. As control,
we used CIR poor cells and IL-10 negative Foxp3neg CD4+ T cells
isolated from the spleens of the same animals. CIR cells were
FACS-sorted as LAG-3, CD49b, and IL-10eGFP High triple posi-
tive, while IL-10-producing Foxp3neg CIR poor CD4+ T cells
were IL-10eGFP High cells not co-expressing LAG-3 and CD49b as
shown in Supplementary Figure 5. As expected, we found a high
number of genes (1051) differentially expressed between IL-10-
producing CIR rich CD4+ T cells and IL-10neg cells (Fig. 5a). The
expression of Il10 and most TR1 related surface receptors and
markers was highly increased in CIR rich cells compared to IL-
10neg cells (Fig. 5b). Also, genes encoding transcription factors
previously linked with the development of TR1 cells such as
Prdm1, Maf, Nfil3, Ahr, and Rora were significantly more
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Fig. 5 CIR rich CD4+ T cells have a distinct transcriptional program. a Volcano plots of bulk RNA sequencing data of indicated populations (IL-10pos CIR
rich n= 2; IL-10pos CIR poor n= 2; IL-10neg n= 2). b Expression of known TR1 signature genes comparing IL-10pos CIR rich with IL-10neg and IL-10pos CIR
rich with IL-10pos CIR poor. c Differentially expressed transcription factors between IL-10pos CIR rich and IL-10pos CIR poor. mRNA expression of indicated
genes normalized to Hprt from at least three independent experiments (separated low-high, line represents median). d CD4+ T cells isolated from Lxrα-/-
CD45.2 and wildtype CD45.2 mice were co-transferred with wildtype CD4+ T cells (CD45.1/2) into lymphopenic hosts. Animals (WT:KO n= 7; WT:WT
n= 6) were treated with aCD3 antibodies 5 weeks upon transfer and cells were isolated from small intestine. Results are cumulative of two independent
experiments. A Wilcoxon test was used to calculate significance. e Correlation between genes significantly higher expressed in IL-10pos CIR rich versus IL-
10pos CIR poor cells and expression pattern of scRNA-seq data
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expressed in CIR rich cells compared to IL-10neg cells (Fig. 5b). In
contrast, between CIR rich and CIR poor cells only 174 genes
were differentially expressed (Fig. 5a). The expression of IL-10
related transcription factors was unaltered between CIR rich and
CIR poor cells, even though the expression of Il10 was slightly
higher in CIR rich cells (Fig. 5b). We therefore approached this
through an unsupervised analysis. We found 11 genes encoding
transcription factors with expression that was higher and 10
where it was lower in CIR rich compared to CIR poor cells. We
confirmed the expression pattern of some of these factors by
qPCR (Fig. 5c). Amongst transcription factors that were more
highly expressed, several have been linked to cell cycle and pro-
liferation such as E2f1, Zbtb16, and Mybl2, indicating a more
proliferative state of CIR rich compared to CIR poor cells53–55.
This data might also suggest that CIR rich cells have a different
activation status than CIR poor cells. We therefore analyzed the
expression of common activation markers of CIR rich and CIR
poor in the scRNA-seq data set. However, we could not detect a
distinct expression pattern of activation markers. Furthermore,
we showed that CIR rich and CIR poor cells have similar CD62L
and CD44 protein expression (Supplementary Figure 7). Thus,
our data disprove a significant difference in the activation status
between CIR poor and rich cells, but rather suggest a different
proliferative status.
In addition, Id2, a factor that we found to be highly expressed
in both Sp C1 and SI C1 in the single cell sequencing data set
(Fig. 2b, d), was also amongst the transcription factors highly
expressed in CIR rich cells (Fig. 5c). Another intriguing
transcription factor selectively expressed in CIR rich cells was
Nr1h3 (Fig. 5d), encoding for Liver X receptor α (LXRα). LXRα
has already been described in macrophages as inhibiting pro-
inflammatory pathways; furthermore, new evidence shows that
LXR activation can induce Foxp3+ regulatory T cells with
superior suppressive function56–59. Consequently, to prove that
our sequencing analysis identified relevant transcription factors
for the biology of IL-10-producing Foxp3neg CIR rich CD4+
T cells, we tested the function of LXRα. To this end, we co-
transferred CD4+ T cells from Lxrα-/- mice together with
congenic wild-type CD4+ T cells into lymphopenic hosts (gating
strategy displayed in Supplementary Figure 8). This co-transfer
approach helped to discriminate between cell intrinsic and
extrinsic effects. After re-population of the recipients with CD4+
T cells we induced IL-10-producing T cells by treating the
animals with anti-CD3 antibodies. Of note, the overall IL-10
production by Lxrα-/- CD4+ T cells was not reduced but it even
increased. However, we found significantly less IL-10-producing
Foxp3neg CIR rich CD4+ T cells, identified for simplicity as
CD49b and LAG-3 co-expressing cells, among the Lxrα-/- CD4+
T cells compared to wild type CD4+ T cells (Fig. 5d). These data
indicate that LXRα indeed does not inhibit the development of
IL-10-producing Foxp3neg CD4+ T cells, but may affect the
biology of IL-10-producing Foxp3neg CIR rich CD4+ T cells
within those (Fig. 5d).
Finally, we wanted to test which subpopulations of IL-10-
producing Foxp3neg CD4+ T cells identified by single-cell
sequencing express the gene signature of CIR rich T cells
identified by bulk RNA sequencing. To this end, we correlated the
expression pattern of each cell from the scRNA-seq analysis with
the expression pattern of CIR rich cells (Fig. 5e). We observed
that cells in Sp C1 and SI C1/C2 showed higher correlation to the
gene signature of CIR rich cells (Fig. 5e). This result further
corroborates our previous findings that these clusters are enriched
for CIR rich cells (Fig. 1f). Moreover, this analysis enabled us to
link the CIR rich cells, identified by the expression of surface
molecules, with clusters of cells that we identified using scRNA-
seq analysis.
In summary, we identified the transcriptional program of
regulatory CIR rich cells which goes beyond the regulation of IL-
10.
Deficiency of CIR rich CD4+ T cells in IBD. We next aimed to
translate these findings into human biology. To that end we
performed scRNA-seq analysis of IL-10-producing CD4+ T cells
isolated from the blood (PBMCs) of three healthy donors. After
quality control, cell cycle filtering and normalization, we analyzed
4438 IL-10-producing T cells pooled from donor 1 and donor 2.
Moreover, we tested 5171 cells form a 3rd donor and in this case
we also included CD25high CD127low CD4+ T cells as control.
This is a cell population, which is indeed known to be func-
tionally heterogeneous6. Using t-SNE analysis, we identified 3 and
2 different clusters among IL-10-producing CD4+ T cells from
donor 1/2 and donor 3, respectively (Fig. 6a). Moreover, using the
analysis of donor 3, we observed that IL-10-producing CD4+
T cells are very distinct from CD25high CD127low CD4+ T cells.
As expected6 these cells formed even more clusters than IL-10-
producing CD4+ T cells (Fig. 6a and Supplementary Figure 9A).
The formation of at least two clusters suggested heterogeneity of
human IL-10-producing CD4+ T cells, albeit at a lower grade
compared to the functionally heterogeneous CD25high CD127low
CD4+ T cells. To further assess the heterogeneity of IL-10-
producing CD4+ T cells, we performed bootstrap analysis of
highly variable genes (HVGs). We found that IL-10-producing
CD4+ T cells appear to be slightly less heterogeneous than
CD25high CD127low CD4+ T cells. However, when we compared
IL-10-producing CD4+ T cells with the clusters C4, C5, and C6,
which are rich in FOXP3high IL2Rhigh CD127low cells and have
previously been proved to be the bona-fide FOXP3+ Treg cells,
we observed instead that IL-10-producing CD4+ T cells are more
heterogeneous (Fig. 6a, Supplementary Figure 9B and C).
Overall, these data indicate that also human IL-10-producing
CD25low CD4+ T cells are a heterogonous population.
To further test this we then performed viSNE analysis on the
basis of the expression of PD-1, LAG-3, TIGIT, TIM-3, CD49b,
and CCR5 in IL-10-producing CD25low CD4+ T cells. First we
confirmed that the IL-10 producing CD4+ T cells express
significantly higher level of the tested surface molecules compared
to the IL-10neg CD4+ T cells (Supplementary Figure 10B). Then
we found that a fraction of intestinal and circulatory humans
CD4+ T cells co-expressed all the tested surface molecules, i.e.
CIR cells (Fig. 6b). Furthermore, we confirmed that co-expression
of only IL-10, CD49b, and LAG-3 showed the highest sensitivity
to enrich for these human CIR rich cells (Supplementary
Figure 10A). Additionally, we excluded the possibility that
FOXP3+ Treg ‘contaminated’ the analyzed population of
CD25low memory CD4+ T cells (Supplementary Figure 10B).
Most importantly, we observed a stronger suppressive capacity of
IL-10-producing CD25low CIR cells compared to CIR poor cells
(Fig. 6c). Of note, there was no significant difference in IL-10
expression between IL-10-producing CD25low CIR rich and CIR
poor cells (Supplementary Figure 10C). Finally CIR rich cells also
express a higher level of LXRα compared to CIR poor cells
(Supplementary Figure 10D).
All together these findings strengthen the link between the
mouse and human data and the notion that CIR cells are
preserved between species.
Finally, we analyzed IL-10-producing CD25low CD4+ T cells in
IBD patients with CD and Ulcerative Colitis (UC) (Patient
information: Supplementary Figure 11). We could not find
paucity in total IL-10 production in CD4+ T cells in the colon of
IBD patients, or in CD or in UC patients, compared to healthy
controls (Fig. 6d). However, we found a significantly reduced
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frequency of IL-10-producing CD25low CIR rich CD4+ T cells
within the IL-10-producing CD25low CD4+ T cells in IBD
patients (Fig. 6e). Thus, our data indicate that IBD patients do not
have a general defect in IL-10-producing CD4+ T cells, but a
selective paucity in CIR rich cells. This defect seems to be a
common feature of patients with both UC and CD (Fig. 6e).
Discussion
We show here that IL-10-producing Foxp3neg CD4+ T cells are a
functional heterogeneous population of cells: while some of these
cells have an anti-inflammatory function other are potentially
pathogenic. Using the combinatorial expression of co-inhibitory
receptors, it is possible to identify the anti-inflammatory
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IL-10-producing Foxp3neg CD4+ T cell population. This popu-
lation is conserved across different tissues and species. Finally, we
revealed that the anti-inflammatory IL-10-producing Foxp3neg
CD4+ T cell population is reduced in IBD patients showing that
these patients have a defect in immunological tolerance.
Several co-inhibitory receptors were reported by others and us
to be expressed on IL-10-producing Foxp3neg CD4+ T cells11–
19,22,60. However, it was not clear whether these markers identi-
fied the same or different populations of cells. The visualization of
all these co-inhibitory receptors simultaneously showed that there
are IL-10-producing cells, which are rich in all the co-inhibitory
receptors, tested. The size of this population varied across dif-
ferent tissues and species, but we were always able to find these
cells. Furthermore, these cells - i.e. CIR rich cells - have a strong
regulatory activity. Therefore, this population fits the original
definition of TR1 cells, which is mainly based on the expression of
IL-10 and on the functional activity10. It is still possible that
different combinations of the same co-inhibitory receptors or the
discovery of new co-inhibitory receptors will help to identify
other regulatory populations. However, we think that this should
not lead to the amplification of T cell nomenclature, but rather to
focus on the different biological aspects of the potential sub-
populations of TR1 cells.
We and others reported before, and confirmed as part of this
study, that CD49b/LAG-3 (or PD1/CCR5) can be used to identify
IL-10-producing cells within CD4+ T cells11,12,16,17,61–64. Here
we extended this finding by showing that CD49b/LAG-3 can also
be used to identify the regulatory subset within the functional
heterogeneous population of IL-10-producing CD4+ cells. The
specificity to enrich regulatory IL-10-producing CD4+ T cells is
increased when more markers are combined, at the price of lower
sensitivity. Thus the enrichment strategy can be adjusted
according to the required purity. Interestingly, our data also show
that IL-10-producing Foxp3neg CIR poor are pathogenic,
although they produce similar amounts of IL-10 compared to CIR
rich cells. Thus, other combinations of co-inhibitory receptors
could also help to further study these potentially pathogenic cells.
More importantly, we started revealing the transcriptional
network going beyond the transcriptional regulation of Il10. By
comparing IL-10-producing CD4+ T cells with and without
regulatory activity, we diverged the network regulating only IL-10
from the one regulating the anti-inflammatory identity of these
cells. By doing so, we identified several transcriptional factors,
which now need a further analysis to understand their function in
TR1 biology. An obvious candidate is LXR. It has been shown that
LXRA and LXRB expression is reduced in colon of IBD patients
compared to healthy controls65. Therefore, manipulation of LXR
function and successive induction of highly suppressive IL-10-
producing Foxp3neg CD4+ T cells could be an intriguing ther-
apeutic strategy since LXR activity can be regulated by synthetic
ligands66,67. Of note, a recently published study showed that IL-
10 expression is negatively regulated by 25−OHC via LXRα/β68.
In line with these data, we also observed an increased frequency
of IL-10-producing cells in Lxra-deficient CD4+ T cells compared
to wild type. However the fraction of CIR rich cells was reduced,
suggesting that LXR plays a role in the biology of CIR rich cells. It
is possible that LXR has a different impact on the differentiation
and stability of CIR rich cells, and this requires further experi-
ments. Furthermore, our data suggest a role of Bhlhe40, which
was recently shown to regulate IL-10 expression69. However the
role of Bhlhe40 in the biology of the CIR rich CD4+ T cells
remains to be tested.
The strong anti-inflammatory activity of TR1 cells, has been
proved by others and by us in several preclinical mouse models of
IMIDs11,27,29,60. Additionally, two clinical trials have already been
successfully completed with the use of in vitro induced
TR1 cells13,70. These successful trials, even if preliminary, exem-
plify the difference between a therapy with IL-10, which only
partially succeeded (reviewed in71), and a therapy with the use of
a cell which can produce the right dose of IL-10 in the target
organs and more importantly, can exert regulatory activity
through multiple mechanisms. Here we found, for the first time,
that CIR rich cells are reduced in both UC and CD patients.
These data finally justify the use a TR1-cell based therapy in IBD
patients.
Methods
Mice. C57BL/6 CD45.2, C57BL/6 Rag1-/- CD45.1 were obtained from The Jackson
Laboratory. Foxp3mRFP, IL-10eGFP reporter mice and Lxrα-/- mice are described
elsewhere29,72. Age and sex- matched littermates between 8 and 16 weeks of age
were used.
Lymphocyte isolation from the intestine of mice. Intraepithelial lymphocytes
were collected after removing Peyer’s patches by incubation of the small intestine
with 5 mM EDTA solution at 37 °C for 30 min. Lamina propria lymphocytes were
isolated by digesting the tissue with collagenase IV (100 U; Sigma-Aldrich) at 37 °C
for 45 min. The cells were further separated by a Percoll gradient (GE Healthcare).
Lymphocyte isolation from the lung and liver of mice. Lymphocytes from lung
and liver of mice were isolated by digesting the tissue with collagenase IV (100 U;
Sigma-Aldrich) for 45 min at 37 °C. The cells were further separated by a Percoll
gradient (GE Healthcare).
Flow cytometry. Briefly, after immune cell isolation (described above), cells were
either analyzed freshly (in case of reporter mice) or re-stimulated with PMA/
Ionomycin for 3 h (non-reporter mice) or in vitro re-stimulated with SEB (1 µg/ml)
to detect IL-10 cytokine secretion (in case of human samples).
Panels for FACS analysis mouse: TCRbeta (BV421, BioLegend, clone H57-597
Dilution 1:200, lot B209221), CD4 (BUV737, BD Bioscience, clone GK1.5, Dilution
1:800, lot 5100736/PE/Cy7, BioLegend, clone RM4-5, Dilution 1:400, lot B19204),
CD49b (PE, BioLegend, clone Hma2, Dilution 1:100, lot B148368; FITC,
BioLegend, clone Hma2, Dilution 1:100, lot B178538), LAG-3 (APC, BioLegend,
clone C9B7W, Dilution 1:100, lot B163789), TIM-3 (Biotin, eBioscience, clone
8B.2C12, Dilution 1:200, lot E02985-1632), Strepdavidin (BUV395, BD Bioscience,
clone NA, Dilution 1:200), TIGIT (PerCPCy5.5, eBioscience, clone GIGD7,
Dilution 1:200, lot E15928-104), PD-1 (BV605, BioLegend, clone 29 F.1A12,
Dilution 1:300, lot B227578), CCR5 (PECy7, BioLegend, clone HM-CCR5, Dilution
1:200, lot B220574), CD45.1 (Pacific Blue, Biolegend, clone A20, Dilution 1:400, lot
B191340), CD45.2 (PECy7, BioLegend, clone 104, Dilution 1:400, lot B185406),
and IL-10 (PE-TexasRed, BioLegend, clone JES5-16E3, Dilution 1:100, lot
B243511). For intracellular IL-10 staining, cells were fixed with 4% PFA for 20 min
at RT and permeabilized with 0.1 % NP40 solution for 4 min. Cells were stained for
IL-10 for 1 h at room temperature. Staining for CD49b and LAG-3 was performed
for 30 min at 37 °C.
Fig. 6 Human IL-10-producing CD4+ T cells are heterogeneous. a RNA single cell sequencing data of IL-10pos cells (including Foxp3+ T cells) isolated from
PBMCs of healthy donors (n= 3), stimulated with SEB overnight. b viSNE analysis of IL-10pos CD25low CD4+ T cells from PBMCs of healthy donors (n= 8)
and healthy colon biopsies (n= 4), stimulated with SEB overnight. Clustering is based on MFI of PD-1, LAG-3, TIGIT, TIM-3, CD49b, and CCR5. Blue circle
indicates co-inhibitory receptor rich (CIR rich) region. c In vitro suppression of CIR rich and CIR poor IL-10pos CD25low CD4+ T cells isolated from PBMCs
of healthy donors, stimulated with SEB overnight. Representative histograms of five independent experiments, a paired T-test was used to calculate
significance. d, e Analysis of IL-10pos CD25low CD4+ T cells (d) and expression of CD49b/LAG-3 within those (e) of colon biopsies from IBD patients: UC
active n= 22 (inflamed n= 20, blue dots; non-inflamed n= 17, black dots); UC Remission n= 2, violet dots; CD active n= 9 (inflamed n= 5, blue dots;
non-inflamed n= 6, black dots); CD remission n= 5, violet dots and healthy controls (n= 18). Cells were stimulated with SEB overnight, One-way ANOVA
(multiple comparisons) was used to calculate significance (**p < 0.005)
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Panels for FACS analysis human: CD45RO (BV510, BioLegend, clone UCHL1,
Dilution 1:400, lot B226190), CD4 (BUV395, BD Bioscience, clone SK3, Dilution
1:200, lot 5309778), CD127 (PeCy7, BioLegend, clone A019D5, Dilution 1:400, lot
B223477), CD25 (BV650, BioLegend, clone BC96, Dilution 1:100, lot B198924),
CD49b (APC, eBioscience, clone P1H5, Dilution 1:50, lot 4301298), LAG-3 (PerCP
eFluor710, eBioscience, clone 3DS223H, Dilution 1:20, lot 4321735), TIM-3
(BV785, BioLegend, clone F38-2E2, Dilution 1:100, lot B236242), TIGIT
(AlexaFluor700, R&D Systems, Dilution 1:100, lot AEEA0215071), PD-1 (BV421,
BioLegend, clone EH12.2H7, Dilution 1:100, lot B217577), CCR5 (FITC, BD
Bioscience, Dilution 1:20, lot 5357814), IL-10 (PE, Miltenyi, IL-10 Secretion Assay
– Detection Kit, Cat.# 130-090-434). IL-10 staining was performed using IL-10
secretion assay – detection kit in accordance with the manual (Miltenyi). Staining
for CD49b and LAG-3 was performed for 30 min at 37 °C.
Samples were acquired on an LSR II flow cytometer (BD Bioscience) and
analyzed using Flowjo. Additionally, data were analyzed using the Cytobank
platform (viSNE analysis).
Transient small intestinal inflammation mouse model. Mice were injected with
anti-CD3 (clone 2C11, 15 µg) i.p. twice every other day (injection on day 0 and day
2). Animals were killed 4 h after the second injection. Controls were injected with
isotype-matched antibodies or PBS.
After CD4+ T cell re-population of lymphopenic hosts, animals were injected
with anti-CD3 (clone 2C11) i.p. twice every other day: first injection 3 µg anti-CD3,
second injection 15 µg anti-CD3.
In vivo transfer colitis model. IL-10eGFP+Foxp3mRFP− cells from spleen or
small intestine (Fig. 1) or IL-10eGFP+Foxp3mRFP−CD49b+LAG-3+ and
IL-10eGFP+Foxp3mRFP− not CD49b+LAG-3+ double positive cells from spleen
(Fig. 4) of anti-CD3 treated mice (CD45.2 Foxp3mRFP IL-10eGFP double reporter
mice) were injected i.p. (50.000 cells/mouse) into lymphopenic hosts (CD45.1
Rag1−/−). The weight and endoscopic colitis score were monitored.
In vivo suppression colitis model. IL-10eGFP+ Foxp3mRFP- CD49b+LAG-3+ cells
and Foxp3+ cells of anti-CD3 treated Foxp3mRFP, IL-10eGFP reporter mice
(CD45.2) were injected i.p. (50.000 cells/mouse) into lymphopenic hosts (Rag1−/−
CD45.1) together with IL-10neg cells (50.000 cells/mouse) isolated from the same
animals. The weight and endoscopic colitis score was assessed 5 weeks after
transfer.
Plasmodium berghei infection ANKA (PbA). Pre-experimental mice were i.p.
injected with PbA (2 × 106 infected erythrocytes) and blood was harvested 6 days
post infection. Infected erythrocytes were used to infect the experimental mice (1 ×
105 infected erythrocytes/mouse). Animals were killed for analysis on day 6 post
infection. To assess the level of parasitemia, a blood smear was stained using
WRIGHT stain.
Endoscopic procedure. Colonoscopy was performed in a blinded fashion for
colitis monitoring using the Coloview system (Karl Storz, Germany). Colitis
scoring was based on granularity of mucosal surface, stool consistency, vascular
pattern, translucency of the colon, and fibrin visible (0–3 points for each)11,28,30.
In vitro suppression assay (mouse). Responder T cells (CD4+ CD25−) were
isolated from C57BL/6 wildtype mice using MACS beads (Miltenyi) and labeled
with 5 µM violet dye. Responder cells were activated in the presence of irradiated
APCs and 1.5 µg anti-CD3 (clone 2C11) either alone or combined with the indi-
cated suppressor population in a ratio of 1:1 for 4 days. Proliferation of responder
T cells was measured via flow cytometry.
Lymphocyte isolation from human intestinal tissues. Tissue specimens were
collected directly during the endoscopy, as is stated later on in the study approval
section. After being cleaned with PBS, the tissue was digested in 5 ml full media
containing collagenase IV (100 U, Sigma-Aldrich) for 20 min at 37 °C. The cells
were further separated by a Percoll gradient (GE Healthcare).
PBMC isolation from buffy coats. PBMCs were isolated from buffy coats of
healthy donors using Biocoll separation solution (Biochrom). CD4+ T cells were
further enriched using MACS CD4 beads (Miltenyi).
In vitro suppression assay (human). IL-10posCD49b+LAG-3+ (CD25Low) and
IL-10pos not CD49b+LAG-3+ double positive (CD25Low) CD4 T cells were sorted
using a FACSAria II. In parallel, responder CD4 T cells were sorted from unsti-
mulated PBMCs from the same donor (CD25lowCD127high). Responder T cells
were labeled with CFSE according to manual (2 µM, 8 min, 37 °C). Responder
T cells and suppressor T cells were cultured in a 1:1 ratio in full media in the
presence of Treg inspector beads (Miltenyi) at a ratio of 3 beads/cell for 4 days.
Relative gene expression analysis. RNA from cells was isolated using TRIzol LS
reagent (Life Technology) according to the manual. RNA was subjected to reverse
transcription with SuperScript II (Invitrogen) with oligo(dT) primer. cDNA was
semi quantified using commercially available primer/probe sets from Applied
Biosystems. Samples were analyzed with the change in cycle threshold method.
Results were normalized to hypoxanthine phosphoribosyltransferase (Hprt),
quantified in parallel amplification reactions.
Bulk-seq read processing. Single-end sequencing reads were trimmed using
Trimmomatic followed by Alignment using Tophat and summarized with HTSeq
count.
10XGenomics Drop-seq read processing. Pair-ended UMI-indexed Illumina
reads were demultiplexed using cellranger mkfastq pipeline, trimmed using
Trimmomatic followed by standard CellRanger pipeline in order to perform
alignment to the respective genome (Mm10 or Hg19), read filtering and UMI
counting for each sample. UMI count tables were imported into R environment
(RStudio) for further data analysis.
SMART-seq2 read processing. Pair-ended whole-transcript Illumina reads were
demultiplexed using de-indexed and aligned to the Mm8 mouse genome through
2-pass alignment using STAR73. RPKM expression values were computed using
uniquely aligned reads74 with MULTo correction75.
Bulk RNA-seq data analysis. A standard RNAseq pipeline76,77 was used for data
analysis of bulk-sorted cell populations (IL10posCD49b+LAG-3+, IL10pos not
CD49b+LAG-3+ double positive, IL10neg not CD49b+LAG-3+ double positive).
Briefly, mitochondrial genes were excluded from the analysis as well as genes that
fail to have over 5 counts in more than 4 samples. Data normalization, model
fitting, and computation of fold changes were done using DESeq277. Genes with
fold change above 1.5 and FDR below 1% were considered differentially expressed
between each pairwise comparison.
Single cell data analyses. A similar analysis strategy78 was applied to both
SMARTseq-2 and 10XGenomics datasets and is described briefly as follows. Cells
were filtered out based on the library size, number of genes, and mitochondrial
gene proportion using 3 median absolute deviations below the median log-library
size for each parameter. Cell classification was performed using Cyclone79 in order
to filter out dividing G2/M cells. Genes with mean row counts below 1 (0.05 for
10 × ) were considered to be of low-abundance and were removed. Data normal-
ization was performed using pool counts method80 and using ERCC spike-in
correction when available. Normalized log-expression values were used for iden-
tification of HVGs with biological variance greater than 0.5 (0.05 for 10 × ) and
false discovery rate of 5%. Normalized log-expression values of HVGs were sub-
sequently processed for non-linear dimensionality reduction using Rtsne (http://
CRAN.R-project.org/package=Rtsne) and further clustering using DBSCAN
(https://CRAN.R-project.org/package=dbscan/) on tSNE space. Differential gene
expression among clusters was done using SCRAN78 and Gene Ontology enrich-
ment analysis was performed using EnrichR. Annotation of cytokines, transcrip-
tion factors, and receptors used are a consensus of several gene annotation
databases. Plots were generated using R base graphics, heatmap, vioplot and
RColorBrewer (https://CRAN.R-project.org/package=pheatmap; https://CRAN.R-
project.org/package=vioplot; http://CRAN.R-project.org/package=RColorBrewer).
For correlation between mouse single cell clusters from both spleen and small
intestine, gene averages per clusters were used. Non-parametric Spearman
correlation was applied in all non-zero values between each clusters compared,
individually. For correlations using bulk RNA-seq, TR1 cell (IL10posCD49b/LAG-
3) gene-wise counts were averaged and correlated iteratively to each cell using only
the HVGs, respective to the single-cell dataset being used.
For comparing gene heterogeneity between spleen and small intestine single cell
datasets, we opted to compute the difference in the number of HVGs in each
dataset by bootstrap. For this purpose, 100 cells were randomly selected and used
to compute the number of HVGs (as indicated above) for each dataset. This
process was repeated 100 times with another 100 randomly picked cells, with
replacement at each time, and the number of HVGs was recorded. Results obtained
this way presented a normal distribution and were compared using two-tailed
Student’s t-test. P values below 0.05 were considered significant.
Statistics. For non-transcriptomic data, two-tailed Mann–Whitney U test, paired
t-test, Wilcoxon test, or one-way ANOVA (with Tukey post-hoc test) test were used
to calculate significance, where applicable. P values below 5% were considered
significant. Statistical calculation was performed using Prism program 5.0
(GraphPad Software).
Study approval. Experiments involving animals were carried out in accordance
with the Institutional Review Board “Behörde für Soziales, Familie, Gesundheit und
Verbraucherschutz” (Hamburg, Germany). Experiments were carried out in
accordance to all relevant ethical regulations.
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Human studies were approved by the local ethical committee (Ethik-
Kommission der Ärztekammer Hamburg). Consent was obtained from all human
participants and experiments were carried out in accordance with all relevant
ethical regulations.
Data availability
All RNA-seq data generated is available at Gene Expression Omnibus (GEO) under
the accession number GSE121393. All other relevant data are available from the
authors.
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